Cardiogen (Ala-Glu-Asp-Arg): Myocardial Tissue Culture and a Sarcoma Model

Cardiogen has two published studies naming it — one in myocardial tissue culture from young and old rats, one reporting a tumour-modifying effect in senescent rats. Both are ageing-model designs.

· · 2 min read
cardiogen bioregulator khavinson Ala-Glu-Asp-Arg AEDR myocardium cardiovascular ageing

Key Research Findings

  • Cardiogen is the tetrapeptide Ala-Glu-Asp-Arg (AEDR), C18H31N7O9, 489.49 g/mol.
  • Two studies name it, both in ageing models.
  • The myocardial tissue-culture study compares young against old donor tissue and co-administers amino acids, limiting attribution.
  • The second study is an oncology model (M-1 sarcoma in senescent rats), not a cardiac one.
  • Published work often does not sit in the tissue these compounds are named for — a recurring pattern in this family.
  • No amount is established for any species.

What Cardiogen Is

Cardiogen is a synthetic tetrapeptide, Ala-Glu-Asp-Arg (AEDR), C18H31N7O9, 489.49 g/mol. Within the bioregulator family it is the cardiac-associated member.

It shares the Ala-Glu-Asp opening with Cartalax, Epithalon and Cortagen, differing only in its C-terminal residue — arginine, which makes it the strongly basic member of the AED series.

Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.

What the Two Studies Report

Myocardial tissue culture, young and old

The study most relevant to the cardiac label examines the effect of amino acids and cardiogen on the development of myocardial tissue culture from young and old rats (Chalisova et al., Adv Gerontol 2009, PMID 20210190).

Two features shape how it should be read. The design compares young against old donor tissue, so any reported effect is age-conditional rather than general. And the peptide is examined alongside amino acids, which limits how cleanly results attach to the tetrapeptide alone.

M-1 sarcoma in senescent rats

The second paper reports a tumour-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats (Levdik et al., Bull Exp Biol Med 2009, PMID 20396706).

Note that this is an oncology model, not a cardiac one — a pattern that recurs across this family, where the published work often does not sit in the tissue the compound is named for. Vilon shows the same shape.

Reading the Evidence

Both studies are ageing models. Senescent or aged-donor systems, not healthy-adult or disease models.

One is a combination design. Effects cannot be assigned to the tetrapeptide alone where amino acids are co-administered.

The cardiac label has one supporting study, and it is a tissue-culture design. No amount is established for any species.

Structure and Handling

  • Sequence. Ala-Glu-Asp-Arg (AEDR), tetrapeptide.
  • Formula. C18H31N7O9, 489.49 g/mol.
  • Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
  • Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
  • Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.

Vesugen is the other vascular-associated member and has no compound-specific literature. The AED series — Cartalax, Epithalon, Cortagen — differs from Cardiogen only at the C-terminus. Full family on the bioregulator overview.

Frequently Asked Questions

What is Cardiogen?

Cardiogen is a synthetic tetrapeptide, Ala-Glu-Asp-Arg (AEDR), C18H31N7O9, 489.49 g/mol, classified within the Khavinson bioregulator family as cardiac-associated. Its arginine C-terminus makes it the strongly basic member of the Ala-Glu-Asp series.

What does the research on Cardiogen show?

Two studies name it: one on the effect of amino acids and cardiogen on myocardial tissue culture from young and old rats (PMID 20210190), and one reporting a tumour-modifying effect on M-1 sarcoma in senescent rats (PMID 20396706). Both are ageing-model designs.

Is the cardiac association supported?

By one tissue-culture study, in which the peptide was examined alongside amino acids — so results cannot be cleanly attributed to the tetrapeptide alone. The second study is an oncology model, not a cardiac one.

Is there an established Cardiogen dosage?

No. No controlled human programme exists, so no published figure is available for any population or context.

How does Cardiogen differ from the other AED peptides?

Cartalax (Ala-Glu-Asp), Epithalon (Ala-Glu-Asp-Gly) and Cortagen (Ala-Glu-Asp-Pro) share the same opening three residues. Cardiogen differs only in its C-terminal arginine, which changes its charge profile substantially.

References

  1. Chalisova NI, Zhekalov AN, Ivko OM, Ryzhak GA. The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats Advances in Gerontology (2009)
  2. Levdik NV, Anisimov VN, Khavinson VKh. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats Bulletin of Experimental Biology and Medicine (2009)
Research Use Only: This content is intended for laboratory and scientific research purposes only. It is not intended for human use, medical advice, diagnosis, or treatment. All compounds discussed are for in vitro and preclinical research contexts.

Related Articles

Prostamax (Lys-Glu-Asp-Pro): Chromatin Effects in Human Lymphocytes

Aug 6, 2026 · 2 min

Bronchogen (Ala-Glu-Asp-Leu): DNA Thermostability and a Sequence Discrepancy

Aug 6, 2026 · 2 min

Testagen (Lys-Glu-Asp-Gly): Its Only Published Study Is About Metal Corrosion

Aug 6, 2026 · 2 min